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A NOVEL STRATEGY FOR SELECTIVE DEPLETION OF HOST-REACTIVE
DONOR LYMPHOCYTES BY PHOTODEPLETION IS EFFICIENT AT CLIN-
ICAL SCALE CONDITIONS AND PRESERVES foxp3 REGULATORY T
CELLS
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tional Insitutes of Health, Bethesda, MD; 3. Celmed Biosciences Inc,
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Using an anti-CD25 immunotoxin (IT) for ex vivo selective
depletion (SD), we recently showed that removal of host-reactive
donor T cells is clinically feasible. Nevertheless, there was a con-
cern that the removal of CD4 CD25 foxp3 regulatory T cells
(Tregs) by CD25-IT might favor GVHD. We therefore investi-
gated photodepletion (PD), an alternative approach whereby allo-
activated cells are labeled with the photosensitizing rhodamine-
based dye TH9402, and exposure to light eliminates cells retaining
the dye. PD may offer the possibility of conferring donor immu-
nity without GVHD, permitting allo-SCT without the need for
post-graft immunosuppression. Stimulator cells from human sub-
jects were prepared from leukapheresis MNCs and cultured using
anti-CD3 and 100 IU IL-2. Responder cells (leukapheresis MNCs)
from HLA-mismatched volunteers were cocultured 1:1 with irra-
diated stimulators for 3 days. Cultured cells were incubated in
TH9402 (5.0 and 7.5 microM), followed by exposure to 514 nm
light in the PD light source (Celmed) at a cell concentration of 5
106/ml in FEP plastic bags (American Fluoroseal). Results were
compared with the established small scale standard method. De-
pletion efﬁcacy was studied by FACS and MLR. Effects on Tregs
were investigated using foxp3 RT-PCR and intracellular foxp3
staining. In two large-scale experiments using cells from two do-
nors, both the standard small-scale conditions and the large-scale
conditions resulted in a 9–18-fold and 21–42-fold reduction in
alloreactivity when compared to the untreated MLR control on
day 1 and day 4 after PD. Third-party responses were main-
tained. Effective depletion was observed despite the fact that a
small fraction of CD25 cells (2.7–3.3% of CD4 cells) were still
detectable by FACS on day 4 after PD. RT-PCR for foxp3 in
CD4-selected cells from the ﬁnal SD product showed that a frac-
tion of foxp3 mRNA was conserved. Intracellular foxp3 staining
showed that foxp3 Tregs persisted after PD, and represented 6%
of CD4 cells in untreated responder cells versus 2.1–4.4% of
CD4 cells in the SD product. PD is feasible under large scale
conditions and results in efﬁcient removal of alloreactive lympho-
cytes, while conserving desirable third-party responses. Use of PD
to selectively deplete donor stem cell transplants may further
mitigate the risk of GVHD by conserving Tregs. (This work was
supported in part by a collaborative research and development
agreement between the NHLBI/NIH and Celmed Biosciences
Inc.).
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POST-THAW WASHING PRIOR TO TRANSPLANTATION OF UMBILICAL
CORD BLOOD UNITS (UCB) THAT WERE DEPLETED OF PLASMA BUT
NOT OF RED BLOOD CELLS
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Washing after thawing of frozen UCB used for hematopoietic
stem cell transplantation (HSCT) is widely practiced for the pur-
pose of removal of the cryoprotectant DMSO and free hemoglobin
from lysed red cells; however, frozen peripheral blood stem cells
with similar loads of free hemoglobin and DMSO are often thawed
and infused directly without washing. Recently, similar clinical
outcomes were seen with the standard red cell depleted (RCD)
UCB, whether washing was employed after thawing or not. How-
ever, no data exist on the utility of post-thaw washing for UCB that
were depleted of plasma (PD) but not depleted of red blood cells.
A retrospective analysis was performed on the outcomes of 84
patients in remission without history of prior transplants, who
received either washed (W; n  43) or non-washed (NW; n  40)
PD UCB units for HSCT. Adverse events of any grade occurring
more than once during infusion include hemoglobinuria (9 NW, 1
W), hypertension (6 NW, 4 W), hives (1 NW, 1 W), nausea/vomit
(2 NW) and dyspnea (1 NW, 1 W). One patient developed seizure
and encephalopathy following infusion of a NW PD UCB that
resolved without any sequelae, although relationship to UCB in-
fusion was uncertain. Total nucleated cell recovery after thawing as
reported by transplant centers is higher for NW (median 95% vs
75%). Unadjusted cumulative incidence (U.C.I.) of neutrophil en-
graftment was similar for both groups, 91  5% for NW (n  36)
versus 93 4% for W (n 41), but median time to neutrophil (20
vs 26 days) and platelet engraftment (platelet 20K 47 vs 55 days and
platelet 50K 55 vs 63 days) occurred earlier for NW. U.C.I. for
platelet 20K engraftment was higher for NW (n  28; 92  6%)
than W (n  39; 75  7%). Acute grade III-IV GvHD were 10%
(NW) and 19% (W), and extensive chronic GvHD were 0% (NW)
and 22% (W). TRM were 18  6% (NW) and 20  7% (W), with
relapse rate for malignant cases at 11  7% for NW and 25  8%
for W. One-year OS was 75  7% (n  40) versus 72  8% (n 
43), and 1-year DFS was 69  10% (n  23) versus 54  9% (n 
34) for NW and W, respectively. No clear beneﬁts of post-thaw
washing for PD UCB prior to HSCT was found, except for the
anticipated lower incidence of transient hemoglobinuria. HSCT
with NW PD CBU was at least as efﬁcacious as that using W PD
units with respect to neutrophil engraftment, TRM, relapse rate,
1-year OS, and DFS. Moreover, washing may have a negative
impact on U.C.I. of platelet engraftment and the speed of neutro-
phil and platelet engraftment.
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ACTIVATION AND ENHANCEMENT OF EX VIVO (EvE) EXPANDED
CRYOPRESERVED CORD BLOOD (CB) NATURAL KILLER (NK) CELLS,
CYTOLYTIC POTENTIAL, AND NK RECEPTOR (NKR) EXPRESSION: PO-
TENTIAL ROLE FOR CB NK IN ADOPTIVE CELLULAR IMMUNOTHERAPY
(ACI)
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NK subsets exhibit differential NKR proﬁles including KIR,
C-lectin (NKG2), and natural cytotoxicity receptors (NCR) in-
volved with tumor recognition (Farag et al, Blood, 2002). NKRs
such as NCR (NKp44, NKp46) and NKG2 surface receptors
NKG2D induce NK cell activation and mediated cytolysis (Mor-
etta et al, Curr Opin Immunol, 2004). CB is limited by the absence
of available donor effector cells for infusion after UCBT (Cairo et
al Transfusion, 2005). We demonstrated the ability to EvE in short
term culture with IL-2, IL-7, IL-12, and anti-CD3 (ABCY) cryo-
preserved, thawed, recryopreserved, rethawed, and EvE (CTCTE)
CB with increases in CD3/16/56 bright/dim subsets expressing
KIR3DL1, KIR2DL1/S1, KIR2DL2, and CD94/NKG2A (Ayello/
Cairo et al, BBMT, 25a, 2004). We now compared short-term with
prolonged cultures (4–10 days) on expansion, maturation, and
expression of NCR, NKG2, KIR, and cytolytic mechanisms in
CTCTE CB. Rethawed CB cells (Kurtzberg/Cairo, Transfuison,
2005) were cultured (2–10 days) in media alone or with anti-CD3
(50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml), and IL-12 (10 ng/ml).
NKR expression (CD94, NKG2C, NKG2D, NKp44, NKp46,
KIR2DS4) and intracellular perforin and granzyme B activity were
determined by ﬂow cytometry. Europium release assay measured
NK and LAK cytotoxicity. NK activating KIR2DS4 was increased
day 10 versus 2 in ABCY in both CD3/16/56 dim/bright subsets
(16.9 0.4 vs 2.1 0.2% and 22.3 0.3 vs 0.9 0.2%, P .001,
respectively). CD94/NKG2D expression was increased day 7 ver-
sus 2 in ABCY EvE (41.4  0.43 vs 23.7  2.0%, P  .001). NK
(CD3/16/56dim) KIR3DL1 subset was increased day 10 versus
2 (38.3  2.8 vs 18.9  6.37%, P  .05). CD3/16/56dim
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